401 related articles for article (PubMed ID: 17847085)
1. Epitope mapping and structural analysis of an anti-ErbB2 antibody A21: Molecular basis for tumor inhibitory mechanism.
Hu S; Zhu Z; Li L; Chang L; Li W; Cheng L; Teng M; Liu J
Proteins; 2008 Feb; 70(3):938-49. PubMed ID: 17847085
[TBL] [Abstract][Full Text] [Related]
2. A novel ErbB2 epitope targeted by human antitumor immunoagents.
Troise F; Monti M; Merlino A; Cozzolino F; Fedele C; Russo Krauss I; Sica F; Pucci P; D'Alessio G; De Lorenzo C
FEBS J; 2011 Apr; 278(7):1156-66. PubMed ID: 21288302
[TBL] [Abstract][Full Text] [Related]
3. Interactions between anti-ErbB2 antibody A21 and the ErbB2 extracellular domain provide a basis for improving A21 affinity.
Chang L; Zhou C; Xu M; Liu J
J Comput Aided Mol Des; 2010 Jan; 24(1):37-47. PubMed ID: 20012671
[TBL] [Abstract][Full Text] [Related]
4. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
Nielsen UB; Adams GP; Weiner LM; Marks JD
Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810
[TBL] [Abstract][Full Text] [Related]
5. Biological effects of anti-ErbB2 single chain antibodies selected for internalizing function.
Neve RM; Nielsen UB; Kirpotin DB; Poul MA; Marks JD; Benz CC
Biochem Biophys Res Commun; 2001 Jan; 280(1):274-9. PubMed ID: 11162510
[TBL] [Abstract][Full Text] [Related]
6. Codon optimization, expression, and characterization of an internalizing anti-ErbB2 single-chain antibody in Pichia pastoris.
Hu S; Li L; Qiao J; Guo Y; Cheng L; Liu J
Protein Expr Purif; 2006 May; 47(1):249-57. PubMed ID: 16403645
[TBL] [Abstract][Full Text] [Related]
7. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
Biburger M; Weth R; Wels WS
J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482
[TBL] [Abstract][Full Text] [Related]
8. Single-chain antibody-mediated gene delivery into ErbB2-positive human breast cancer cells.
Li X; Stuckert P; Bosch I; Marks JD; Marasco WA
Cancer Gene Ther; 2001 Aug; 8(8):555-65. PubMed ID: 11571533
[TBL] [Abstract][Full Text] [Related]
9. Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line.
Nagy P; Friedländer E; Tanner M; Kapanen AI; Carraway KL; Isola J; Jovin TM
Cancer Res; 2005 Jan; 65(2):473-82. PubMed ID: 15695389
[TBL] [Abstract][Full Text] [Related]
10. De novo design of ErbB2 epitope targeting fusion protein stabilized by coiled coil structure.
Wang J; Feng J; Shi M; Qian L; Chen L; Yu M; Xu R; Shen B; Guo N
Mol Immunol; 2008 Jan; 45(1):106-16. PubMed ID: 17572496
[TBL] [Abstract][Full Text] [Related]
11. Construction, expression and characterization of the engineered antibody against tumor surface antigen, p185(c-erbB-2).
Cheng LS; Liu AP; Yang JH; Dong YQ; Li LW; Wang J; Wang CC; Liu J
Cell Res; 2003 Feb; 13(1):35-48. PubMed ID: 12643348
[TBL] [Abstract][Full Text] [Related]
12. Neutralization of NGF-TrkA receptor interaction by the novel antagonistic anti-TrkA monoclonal antibody MNAC13: a structural insight.
Covaceuszach S; Cattaneo A; Lamba D
Proteins; 2005 Feb; 58(3):717-27. PubMed ID: 15625712
[TBL] [Abstract][Full Text] [Related]
13. Selection, affinity maturation, and characterization of a human scFv antibody against CEA protein.
Pavoni E; Flego M; Dupuis ML; Barca S; Petronzelli F; Anastasi AM; D'Alessio V; Pelliccia A; Vaccaro P; Monteriù G; Ascione A; De Santis R; Felici F; Cianfriglia M; Minenkova O
BMC Cancer; 2006 Feb; 6():41. PubMed ID: 16504122
[TBL] [Abstract][Full Text] [Related]
14. Differential binding of human immunoagents and Herceptin to the ErbB2 receptor.
Troise F; Cafaro V; Giancola C; D'Alessio G; De Lorenzo C
FEBS J; 2008 Oct; 275(20):4967-79. PubMed ID: 18795950
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis.
Vajdos FF; Adams CW; Breece TN; Presta LG; de Vos AM; Sidhu SS
J Mol Biol; 2002 Jul; 320(2):415-28. PubMed ID: 12079396
[TBL] [Abstract][Full Text] [Related]
16. Affinity maturation of antiHER2 monoclonal antibody MIL5 using an epitope-specific synthetic phage library by computational design.
Qiao C; Lv M; Li X; Geng J; Li Y; Zhang J; Lin Z; Feng J; Shen B
J Biomol Struct Dyn; 2013; 31(5):511-21. PubMed ID: 23003339
[TBL] [Abstract][Full Text] [Related]
17. Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site.
Schier R; McCall A; Adams GP; Marshall KW; Merritt H; Yim M; Crawford RS; Weiner LM; Marks C; Marks JD
J Mol Biol; 1996 Nov; 263(4):551-67. PubMed ID: 8918938
[TBL] [Abstract][Full Text] [Related]
18. Selection of tumor-specific internalizing human antibodies from phage libraries.
Poul MA; Becerril B; Nielsen UB; Morisson P; Marks JD
J Mol Biol; 2000 Sep; 301(5):1149-61. PubMed ID: 10966812
[TBL] [Abstract][Full Text] [Related]
19. Mapping of binding epitopes of a human decay-accelerating factor monoclonal antibody capable of enhancing rituximab-mediated complement-dependent cytotoxicity.
Guo B; Ma ZW; Li H; Xu GL; Zheng P; Zhu B; Wu YZ; Zou Q
Clin Immunol; 2008 Aug; 128(2):155-63. PubMed ID: 18502181
[TBL] [Abstract][Full Text] [Related]
20. Molecular basis for the binding polyspecificity of an anti-cholera toxin peptide 3 monoclonal antibody.
Otte L; Knaute T; Schneider-Mergener J; Kramer A
J Mol Recognit; 2006; 19(1):49-59. PubMed ID: 16273596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
